<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | Accelerating Medicines Partnership for Parkinson's Disease (AMP-PD)
|-
| Established | 2019
|-
| Type | Public-Private Partnership
|-
| Lead Agencies | NIH (NINDS, NIA), FDA
|-
| Pharma Partners | 12+ pharmaceutical companies
|-
| Focus | Biomarker discovery and target validation
|}
</div>
<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | Accelerating Medicines Partnership for Parkinson's Disease (AMP-PD)
|-
| Established | 2019
|-
| Type | Public-Private Partnership
|-
| Lead Agencies | NIH (NINDS, NIA), FDA
|-
| Pharma Partners | 12+ pharmaceutical companies
|-
| Focus | Biomarker discovery and target validation
|}
</div>
The Accelerating Medicines Partnership for Parkinson's Disease (AMP-PD) is a landmark public-private partnership designed to accelerate the development of new therapies for Parkinson's disease. By bringing together the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and multiple pharmaceutical companies, AMP-PD aims to identify and validate biomarkers, understand disease mechanisms, and enable more efficient clinical trials.
Parkinson's disease drug development faces significant challenges:
AMP-PD addresses these challenges through:
| Institute | Role |
|-----------|------|
| NINDS | Primary scientific lead |
| NIA | Aging and biomarker expertise |
| NCATS | Translational science support |
| NHLBI | Cardiovascular comorbidity expertise |
AMP-PD includes major pharmaceutical companies:
| Company | Contributions |
|---------|---------------|
| Biogen | Clinical trial data, expertise |
| Bristol Myers Squibb | Research collaboration |
| Eli Lilly | Compound libraries |
| Merck | Biomarker assays |
| Pfizer | Clinical data |
| Roche | Diagnostics development |
| Takeda | Research collaboration |
| Verily | Data analytics |
AMP-PD focuses on identifying:
| Biomarker Type | Clinical Application |
|----------------|---------------------|
| Diagnostic | Early PD detection |
| Progression | Disease staging |
| Prognostic | Outcome prediction |
| Pharmacodynamic | Drug target engagement |
The partnership validates therapeutic targets:
| Target | Approach | Status |
|--------|---------|--------|
| [Alpha-synuclein](/proteins/alpha-synuclein) | Seeding assays | Validated |
| [LRRK2](/entities/lrrk2) | Kinase activity | In validation |
| [GBA1](/entities/gba) | Enzyme activity | In validation |
| [Tau](/proteins/tau) | Phospho-species | Exploratory |
AMP-PD aggregates clinical data from:
The program provides open-access data:
| Data Type | Samples | Access |
|-----------|---------|--------|
| Clinical data | 10,000+ | Open |
| Genomic data | 8,000+ | Open |
| Proteomics | 5,000+ | Open |
| Imaging | 3,000+ | Open |
Industry Data → Harmonization → AMP-PD Platform →
Academic Analysis → Public Release → Published Findings
This pre-competitive model enables:
AMP-PD has advanced alpha-synuclein biomarkers:
| Biomarker | Technology | Clinical Use |
|-----------|------------|--------------|
| α-synuclein RT-QuIC | Seed amplification | Diagnostic |
| CSF total α-syn | ELISA | Monitoring |
| CSF phosphorylated | ELISA | Target engagement |
| PET ligands | Imaging | Protein burden |
The program integrates genetics with clinical data:
Longitudinal data enables progression marker discovery:
| Marker | Change with Progression | Utility |
|--------|------------------------|---------|
| Motor scores | Worsening | Clinical trials |
| Cognitive tests | Decline | Prognosis |
| Imaging markers | Atrophy | Monitoring |
| CSF biomarkers | Dynamic | Target engagement |
AMP-PD has been instrumental in developing and validating alpha-synuclein seed amplification assays (SAAs), including RT-QuIC (Real-Time Quaking-Induced Conversion) and PMCA (Protein Misfolding Cyclic Amplification)[@chen2023]. These assays detect misfolded alpha-synuclein in cerebrospinal fluid with high sensitivity (≈95%) and specificity (≈90%) for Parkinson's disease.
Key findings from AMP-PD studies:
AMP-PD has established robust assays for measuring LRRK2 kinase activity in biological samples[@khr2023]:
| Assay | Sample Type | Application |
|-------|-------------|-------------|
| pSer935 LRRK2 | Blood (PBMCs) | Target engagement |
| pThr73 Rab10 | Blood | Kinase activity |
| pThr73 Rab10 | CSF | CNS penetration |
| LRRK2 auto-phosphorylation | Cell lines | Compound screening |
These biomarkers have been critical for:
The AMP-PD GBA research program has characterized the largest cohort of glucocerebrosidase (GBA) variant carriers with Parkinson's disease[@chare2023]:
While primarily focused on alpha-synuclein, AMP-PD has also advanced tau biomarkers:
The Parkinson's Progression Markers Initiative (PPMI) is a cornerstone of AMP-PD[@ppmini2023]:
| PPMI Cohort | Participants | Key Features |
|-------------|---------------|--------------|
| De novo PD | 500+ | Untreated, recent diagnosis |
| Prodromal | 200+ | RBD, hyposmia, genetic risk |
| Healthy controls | 200+ | Age-matched |
| Genetic cohorts | 300+ | LRRK2, GBA, SNCA, PARKIN |
| SWEDD | 100+ | Important for diagnosis |
PPMI has generated:
AMP-PD has integrated data from:
| Trial Program | Companies | Data Types |
|---------------|-----------|------------|
| LRRK2 inhibitor trials | Biogen, Denali, Roche | Clinical, biomarker |
| GBA trials | Sanofi, Pfizer | Clinical, genetic |
| Alpha-synuclein trials | Roche, Biogen, Novartis | Clinical, CSF biomarkers |
| Symptomatic trials | Multiple | Clinical, imaging |
This integration enables:
The AMP-PD Knowledge Portal (ampdmarkers.org) provides:
AMP-PD researchers have pioneered:
| Approach | Application | Key Outputs |
|----------|-------------|-------------|
| Multi-omics integration | Systems biology | Novel pathway discovery |
| Machine learning | Risk prediction | Polygenic risk scores |
| Survival analysis | Progression modeling | Prognostic biomarkers |
| Network analysis | Target identification | Module discovery |
AMP-PD has implemented rigorous reproducibility standards:
AMP-PD has contributed to validation of multiple PD therapeutic targets:
| Target | Evidence Level | AMP-PD Contribution |
|--------|----------------|---------------------|
| Alpha-synuclein | Clinical (Phase 3) | Diagnostic biomarkers, patient selection |
| LRRK2 | Clinical (Phase 2) | Pharmacodynamic biomarkers, genetic stratification |
| GBA | Clinical (Phase 1/2) | Target engagement markers, patient enrichment |
| Tau | Preclinical/Phase 1 | Biomarker development |
AMP-PD data has influenced trial design:
AMP-PD resources support drug repurposing:
AMP-PD resources enable better trials:
| Application | Example |
|-------------|---------|
| Patient selection | Genetic stratification |
| Enrichment | Biomarker-positive subjects |
| Outcome measures | Validated endpoints |
| Sample size | Precision medicine |
Data resources support drug repurposing:
AMP-PD contributed to repurposing efforts:
AMP-PD works closely with the [Global Parkinson's Genetics Program](/institutions/gp2):
Pharma partners contribute:
Academic researchers access:
| Year | Key Publication | Impact |
|------|-----------------|--------|
| 2020 | AMP-PD Whitepaper | Program foundation |
| 2021 | Biomarker Landscape | Comprehensive review |
| 2022 | Genetic Stratification | Precision medicine |
| 2023 | Progression Markers | Clinical utility |
| Resource | Purpose |
|----------|---------|
| AMP-PD Knowledge Portal | Data access |
| Analysis notebooks | Reproducible research |
| Biomarker assays | Standardized measurement |
| Data dictionaries | Harmonization |
AMP-PD aims to enable:
The following diagram shows the key molecular relationships involving Accelerating Medicines Partnership for Parkinson's Disease (AMP-PD) discovered through SciDEX knowledge graph analysis: